[1]
|
Johnson, D.E. (2015) The Ubiquitin-Proteasome System: Opportunities for Therapeutic Intervention in Solid Tumors. Endocrine-Related Cancer, 22, T1-17. https://doi.org/10.1530/ERC-14-0005
|
[2]
|
Pal, A., Young, M.A. and Do-nato, N.J. (2014) Emerging Potential of Therapeutic Targeting of Ubiquitin-Specific Proteases in the Treatment of Cancer. Cancer Research, 74, 4955-4966. https://doi.org/10.1158/0008-5472.CAN-14-1211
|
[3]
|
Bethard, J.R., Zheng, H., Roberts, L. and Eblen, S.T. (2011) Identification of Phosphorylation Sites on the E3 Ubiquitin Ligase UBR5/EDD. Journal of Proteomics, 75, 603-609. https://doi.org/10.1016/j.jprot.2011.08.023
|
[4]
|
Grau-Bové, X., Sebé-Pedrós, A. and Ruiz-Trillo, I. (2013) A Genomic Survey of HECT Ubiquitin Ligases in Eukaryotes Reveals Independent Expan-sions of the HECT System in Several Lineages. Genome Biology and Evolution, 5, 833-847.
https://doi.org/10.1093/gbe/evt052
|
[5]
|
Swenson, S.A., Gilbreath, T.J., Vahle, H., et al. (2020) UBR5 HECT Do-main Mutations Identified in Mantle Cell Lymphoma Control Maturation of B Cells. Blood, 136, 299-312. https://doi.org/10.1182/blood.2019002102
|
[6]
|
Munoz-Escobar, J., Matta-Camacho, E., Kozlov, G. and Gehring, K. (2015) The MLLE Domain of the Ubiquitin Ligase UBR5 Binds to Its Catalytic Domain to Regulate Substrate Bind-ing. Journal of Biological Chemistry, 290, 22841- 22850. https://doi.org/10.1074/jbc.M115.672246
|
[7]
|
Wang, D., Xu, Q., Yuan, Q., Jia, M., Niu, H., Liu, X., et al. (2019) Proteasome Inhibition Boosts Autophagic Degradation of Ubiquitinated-AGR2 and Enhances the Antitumor Efficiency of Bevacizumab. Oncogene, 38, 3458-3474.
https://doi.org/10.1038/s41388-019-0675-z
|
[8]
|
De Martino, L., Errico, M.E., Ruotolo, S., Cascone, D., Chiaraval-li, S., Collini, P., et al. (2018) Pediatric Lung Adenocarcinoma Presenting with Brain Metastasis: A Case Report. Journal of Medical Case Reports, 12, 243.
https://doi.org/10.1186/s13256-018-1781-1
|
[9]
|
Dompe, N., et al. (2011) A Whole-Genome RNAi Screen Identi-fies an 8q22 Gene Cluster That Inhibits Death Receptor-Mediated Apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 108, E943-E951. https://doi.org/10.1073/pnas.1100132108
|
[10]
|
Bolt, M.J., Stossi, F., Callison, A.M., Mancini, M.G., Dandekar, R. and Mancini, M.A. (2014) Systems Level-Based RNAi Screening by High Content Analysis Identifies UBR5 as a Regulator of Estrogen Receptor-α Protein Levels and Activity. Oncogene, 34, 154-164. https://doi.org/10.1038/onc.2013.550
|
[11]
|
Song, M., Wang, C., Wang, H., Zhang, T., Li, J., Benezra, R., et al. (2020) Targeting Ubiquitin Protein Ligase E3 Component N-Recognin 5 in Cancer Cells Induces a CD8+ T Cell Mediated Immune Response. Oncoimmunology, 9, Article ID: 1746148. https://doi.org/10.1080/2162402X.2020.1746148
|
[12]
|
Liao, L., Song, M., Li, X., Tang, L., Zhang, T., Zhang, L., et al. (2017) E3 Ubiquitin Ligase UBR5 Drives the Growth and Metastasis of Triple-Negative Breast Cancer. Cancer Re-search, 77, 2090-2101.
https://doi.org/10.1158/0008-5472.CAN-16-2409
|
[13]
|
Qiao, X., Liu, Y., Prada, M.L., Mohan, A.K., Gupta, A., Jaiswal, A., et al. (2020) UBR5 Is Coamplified with MYC in Breast Tumors and Encodes an Ubiquitin Ligase That Lim-its MYC-Dependent Apoptosis. Cancer Research, 80, 1414- 1427. https://doi.org/10.1158/0008-5472.CAN-19-1647
|
[14]
|
Yang, Y., Zhao, J., Mao, Y., Lin, G., Li, F. and Jiang, Z. (2020) UBR5 Over-Expression Contributes to Poor Prognosis and Tamoxifen Resistance of ERa+ Breast Cancer by Stabilizing β-Catenin. Breast Cancer Research and Treatment, 184, 699-710. https://doi.org/10.1007/s10549-020-05899-6
|
[15]
|
Yang, M., Jiang, N., Cao, Q.-W., Ma, M.-Q. and Sun, Q. (2016) The E3 Ligase UBR5 Regulates Gastric Cancer Cell Growth by Destabilizing the Tumor Suppressor GKN1. Biochemical and Biophysical Research Communications, 478, 1624-1629. https://doi.org/10.1016/j.bbrc.2016.08.170
|
[16]
|
Xie, Z., Liang, H., Wang, J., Xu, X., Zhu, Y., Guo, A., et al. (2017) Significance of the E3 Ubiquitin Protein UBR5 as an Oncogene and a Prognostic Biomarker in Colorectal Cancer. Oncotarget, 8, Article ID: 108079-92.
https://doi.org/10.18632/oncotarget.22531
|
[17]
|
Eblen, S.T. and Bradley, A. (2017) MOAP-1, UBR5 and Cisplatin Resistance in Ovarian Cancer. Translational Cancer Research, 6, S18-S21. https://doi.org/10.21037/tcr.2017.02.01
|
[18]
|
Ji, S.Q., et al. (2017) UBR5 Promotes Cell Proliferation and Inhibits Apoptosis in Colon Cancer by Destablizing P21. Pharmazie, 72, 408-413.
|
[19]
|
Wang, J., Zhao, X., Jin, L., Wu, G. and Yang, Y. (2017) UBR5 Contributes to Colorectal Cancer Progression by Destabilizing the Tumor Suppressor ECRG4. Digestive Diseases and Sciences, 62, 2781-2789.
https://doi.org/10.1007/s10620-017-4732-6
|
[20]
|
Leboeuf, D., Abakumova, T., Prikazchikova, T., Rhym, L. ander-son, D.G., Zatsepin, T.S., et al. (2020) Downregulation of the Arg/N-degron Pathway Sensitizes Cancer Cells to Chem-otherapy in Vivo. Molecular Therapy, 28, 1092-1104.
https://doi.org/10.1016/j.ymthe.2020.01.021
|
[21]
|
Zhang, Z., Zheng, X., Li, J., Duan, J., Cui, L., Yang, L., et al. (2019) Overexpression of UBR5 Promotes Tumor Growth in Gallbladder Cancer via PTEN/PI3K/Akt Signal Pathway. Journal of Cellular Biochemistry, 120, 11517-11524.
https://doi.org/10.1002/jcb.28431
|
[22]
|
O’Brien, P.M., Davies, M.J., Scurry, J.P., Smith, A.N., Barton, C.A., Hen-derson, M.J., et al. (2008) Erratum: The E3 Ubiquitin Ligase EDD Is an Adverse Prognostic Factor for Serous Epithelial Ovarian Cancer and Modulates Cisplatin Resistance in Vitro. British Journal of Cancer, 98, 1085-1093. https://doi.org/10.1038/sj.bjc.6604281
|
[23]
|
Bradley, A., Zheng, H., Ziebarth, A., Sakati, W., Branham-O’Connor, M., Blumer, J.B., et al. (2014) EDD Enhances Cell Survival and Cisplatin Resistance and Is a Therapeutic Target for Ep-ithelial Ovarian Cancer. Carcinogenesis, 35, 1100- 1109. https://doi.org/10.1093/carcin/bgt489
|
[24]
|
Matsuura, K., Huang, N.J., Cocce, K., Zhang, L. and Kornbluth, S. (2016) Downregulation of the Proapoptotic Protein MOAP-1 by the UBR5 Ubiquitin Ligase and Its Role in Ovarian Cancer Resistance to Cisplatin. Oncogene, 36, 1698- 1706. https://doi.org/10.1038/onc.2016.336
|
[25]
|
Song, M., Yeku, O.O., Rafiq, S., Purdon, T., Dong, X., Zhu, L., et al. (2020) Tumor Derived UBR5 Promotes Ovarian Cancer Growth and Metastasis through Inducing Immunosuppressive Macrophages. Nature Communications, 11, Article No. 6298. https://doi.org/10.1038/s41467-020-20140-0
|
[26]
|
Sun, J., Yang, X., Zhang, R., Liu, S., Gan, X., Xi, X., et al. (2017) GOLPH3 Induces Epithelial-Mesenchymal Transition via Wnt/β-Catenin Signaling Pathway in Epithelial Ovarian Cancer. Cancer Medicine, 6, 834-844.
https://doi.org/10.1002/cam4.1040
|